Crescent Biopharma vs Whitehawk Therapeutics
CBIO and WHWK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBIO and WHWK compare
Crescent Biopharma is the larger company, worth 3.0 times as much as Whitehawk Therapeutics ($534M against $175M).
Crescent Biopharma scores higher on the StockData Score (10 against 8 for Whitehawk Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBIO | WHWK |
|---|---|---|
| Size and price | ||
| Market cap | $534M | $175M |
| Share price | $14.37 | $3.07 |
| Change, 1 year | 8.5% | 37.7% |
| Change, 5 years | −92.4% | −87.6% |
| Beta (5Y) | 1.63 | 0.75 |
| Employees | 44 | 23 |
| StockData Score | ||
| Total score | 10 (better) | 8 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 35.6× | – |
| P/B | 1.9× | 1.1× (better) |
| FCF yield | −15.4% (better) | −42.1% |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | 1.3% (better) | −12.6% |
| Profitability | ||
| Operating margin | −1217% | – |
| Net margin | −728% | – |
| FCF margin | −550% | – |
| Return on equity | −55.8% | −52.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 12.57 | 16.47 (better) |
| Altman Z-score | 10.62 (better) | 6.06 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 79.7% | 75.8% |
| Held by insiders | 38.6% | 49.9% |
| Insider net buying, 12 months | $29.1M (better) | −$2.6M |
| Short interest, % of float | 18.3% | 8.7% |
Go deeper
- CBIO stock overview
- CBIO income statement
- CBIO valuation and score
- WHWK stock overview
- WHWK income statement
- WHWK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.